DOI: https://doi.org/10.61427/jcpr.v4.i1.2024.119.
V. Jyothi Krishna et al., J.Clin.Pharm.Res., 2024; 4(1): 11-16.

Journal of
Clinical and Pharmaceutical Research

REVIEW OPEN ACCESS

Integrating Immunotherapy and Nanotechnology in Advanced Drug Delivery Systems for Precision Cancer Therapy

V. Jyothi Krishna[1*], L. Swathi[2], S. Surya Lakshmi[3]

[1]Department of Pharmaceutics, Srinivasarao College of Pharmacy, Visakhapatnam, Andhra Pradesh, India.
[2]Department of Pharmaceutical Analysis, Srinivasarao College of Pharmacy, Visakhapatnam, Andhra Pradesh, India.
[3]Department of Pharmacy Practice, Srinivasarao College of Pharmacy, Visakhapatnam, Andhra Pradesh, India.

ARTICLE INFO

Article History:
Received: 12.12.2023
Revised: 07.01.2024
Accepted: 11.01.2024

Keywords :
Immunotherapy
Nanotechnology
Precision Cancer Therapy

Corresponding Author:
Mr. V. Jyothi Krishna M.Pharm
Associate Professor
Department of Pharmaceutics,
Srinivasarao College of Pharmacy,
Visakhapatnam,
Andhra Pradesh, India.
Email: jyok0286@gmail.com

ABSTRACT

This review article investigates recent advancements in drug delivery systems, with a specific emphasis on integrating nanotechnology and immunotherapy for precision cancer therapy. This review explores the design, development, and optimization of novel drug delivery platforms aimed at improving drug efficacy, minimizing side effects and enhancing patient outcomes. The synergistic interplay between nanocarriers and immunotherapeutic agents shows significant potential in addressing current challenges in cancer treatment, such as drug resistance and off-target effects. This article reviews recent preclinical and clinical studies, highlighting the transformative potential of these innovative approaches to reshape cancer therapeutics and facilitate the advent of personalized medicine in oncology. The research findings contribute to the ongoing initiatives aimed at refining the effectiveness and safety of pharmaceutical interventions, bringing us one step closer to more efficient and targeted cancer treatments.

Introduction

In recent years, there has been notable advancement in cancer therapy, propelled by inventive strategies that leverage the capabilities of nanotechnology and immunotherapy. The intersection of these state-of-the-art disciplines has opened avenues for sophisticated drug delivery systems, heralding a novel era in precision cancer therapy [1].

Immunotherapy in Cancer Management

Immunotherapy stands out as an innovative and auspicious strategy in cancer management, leveraging the innate capabilities of the body's immune system to identify and eliminate malignant cells. In this segment, we delve into the fundamental principles, mechanisms and contemporary applications of immunotherapy within the dynamic framework of cancer treatment [2-5].

Mechanisms of Immunotherapeutic Action

Appreciating the nuanced workings of immunotherapeutic interventions is crucial for individuals seeking to recognize the transformative impact of this approach in fortifying the body's immune defences against cancer [6]. In the activation and empowerment of immune cells, the intervention seeks to stimulate key immune cells, particularly T cells and natural killer (NK) cells, which play pivotal roles in identifying and eliminating abnormal cells, including cancer cells. The focus of immunotherapy interventions is to enhance the surveillance and targeting capabilities of these immune effectors [7]. At the core of immunotherapy lies the modulation of immune checkpoints, regulatory proteins maintaining the delicate balance of the immune system. Certain cancers exploit these checkpoints to evade immune detection. Specifically, checkpoint inhibitors disrupt these inhibitory signals, empowering the immune system to mount a robust response against cancer cells [8].

Immunotherapy incorporates the utilization of therapeutic vaccines designed to educate the immune system to recognize and combat cancer cells. These vaccines may encompass tumor-specific antigens or induce the production of immune cells targeting cancer-associated proteins. By priming the immune system, therapeutic vaccines augment its ability to identify and eradicate cancerous cells [9]. Cytokine modulation within immunotherapy involves the strategic administration of specific cytokines, such as interleukins and interferons, which are pivotal signaling molecules orchestrating immune responses. This modulation amplifies the activity of immune cells, enhancing the immune system's effectiveness in recognizing and eliminating cancer cells [10]. In the activation of antigen-presenting cells (APCs), including dendritic cells, immunotherapies stimulate the activation and maturation of these cells, enhancing their capacity to present cancer-specific antigens to T cells. This process reinforces the immune system's ability to recognize and target malignant cells [11].

Enhancement through antibody-dependent cellular cytotoxicity (ADCC) is integral to immunotherapy. Monoclonal antibodies engage immune cells through ADCC, a mechanism wherein immune cells are recruited to target cells marked by antibodies. This engagement leads to the destruction of these marked cells, heightening the precision of immune responses against cancer [12].

Current Challenges in Immunotherapy

In cancer treatment, immunotherapy stands out as a groundbreaking and transformative approach, but it grapples with persistent challenges affecting its widespread applicability and efficacy [13].

Addressing Challenges in Response Rates

Immunotherapy encounters a substantial challenge in the variability of response rates among patients. While some individuals exhibit remarkable and enduring responses, others may demonstrate limited or no response. Unraveling the factors influencing this heterogeneity and devising strategies to enhance response rates are crucial endeavors to broaden the impact of immunotherapeutic interventions [14].

Confronting Resistance Development

Analogous to other cancer treatments, immunotherapy contends with the development of resistance over time. Cancer cells may adapt and evolve mechanisms to evade immune recognition and destruction. Understanding the dynamics of resistance mechanisms and formulating approaches to overcome or prevent resistance are pivotal for sustaining the long-term effectiveness of immunotherapy [15].

Managing Autoimmune Complications

Activating the immune system to target cancer cells may inadvertently lead to immune-related adverse events, including autoimmune reactions where the immune system attacks healthy tissues. Balancing therapeutic benefit with the risk of autoimmune side effects presents a delicate challenge. Ongoing research focuses on refining the specificity of immunotherapies to minimize off-target effects [16].

Exploring Biomarker Identification

Predicting which patients will respond favorably to immunotherapy remains a considerable challenge. Biomarkers that reliably indicate a patient's likelihood of response are indispensable for personalized treatment strategies. Current efforts concentrate on identifying and validating biomarkers to guide treatment decisions and enhance the precision of immunotherapeutic interventions [17].

Optimizing Combination Therapies

The combination of different immunotherapeutic agents or the integration of immunotherapy with other treatment modalities holds great promise. However, determining optimal combinations, sequencing and dosages is a complex task. Striking the right balance to maximize the therapeutic synergy while minimizing the adverse interactions will be an ongoing challenge in this field [18].

Addressing Access and Affordability Challenges

The elevated costs associated with some immunotherapies pose obstacles to their accessibility and affordability for a broader patient population. Addressing cost-related barriers and exploring avenues for improving the cost-effectiveness of these treatments are crucial to ensure equitable access and maximize their impact on cancer care [19].

Exploring Beyond Solid Tumors

Despite remarkable success in treating certain solid tumors, the effectiveness of immunotherapy against hematological malignancies and other cancer types remains under investigation. Expanding the applicability of immunotherapy to a broader spectrum of cancers necessitates a deeper understanding of the unique challenges posed by different malignancies [20]. Navigating these challenges is imperative for unlocking the full potential of immunotherapy and establishing it as a cornerstone in the arsenal against cancer. Ongoing research endeavors and collaborative efforts within the scientific community aim to address these hurdles, fostering continual advancements in the field of cancer immunotherapy [21].

Synergies with Nanotechnology

In exploring the advancements at the intersection of nanotechnology and cancer immunotherapy, the collaborative efforts between these fields have become apparent, presenting novel possibilities for elevated therapeutic outcomes. The following overview delves into the dynamic partnership between nanotechnology and immunotherapy, emphasizing the transformative potential derived from their integration in the ongoing battle against cancer [22].

Precision Drug Delivery

Nanotechnology, serving as a precise orchestrator of drug delivery, facilitates the targeted transport of immunotherapeutic agents. Nano-sized carriers, such as liposomes or nanoparticles, encapsulate and ferry immunomodulatory drugs directly to cancer cells or the tumor microenvironment. This meticulous control reduces off-target effects, amplifying the therapeutic impact on malignant tissues [23].

Improved Pharmacokinetics

Nanocarriers contribute to the enhanced pharmacokinetics of immunotherapeutic agents. The encapsulation of these agents within nanoparticles extends their circulation time in the bloodstream, ensuring sustained release and increased exposure to immune cells. This optimization enhances the overall efficacy of immunotherapy by prolonging the therapeutic effect [24].

Enhanced Cellular Uptake

Nanoparticles play a pivotal role in facilitating heightened cellular uptake of immunotherapeutic payloads, particularly advantageous for immune cells like dendritic cells crucial in initiating immune responses. Engineered to promote efficient uptake by these cells, nanocarriers amplify the immunostimulatory effects [25].

Overcoming Biological Barriers

Nanoparticles, distinguished by their unique size and surface properties, successfully overcome biological barriers that might hinder the effective delivery of immunotherapeutic agents. Navigating physiological barriers, including the blood-brain barrier, nanocarriers enable the treatment of cancers in anatomically challenging locations, thereby broadening the scope of immunotherapy [26].

Combination Therapies & Multifunctional Platforms

Nanotechnology's versatility facilitates the seamless integration of multiple therapeutic modalities into a unified platform, enabling the simultaneous delivery of immunotherapeutic agents with complementary treatments such as chemotherapy or targeted therapy. These multifunctional nanoplatforms enhance treatment efficacy through synergistic effects, addressing various aspects of cancer progression [27].

Immunomodulation and Immune Activation

Engineered nanoparticles stand out for their ability to modulate the immune system and enhance the activation of immune cells. Surface modifications and functionalization of nanoparticles stimulate specific immune responses, promoting the recognition and targeting of cancer cells. This immunomodulatory capability complements the mechanisms of immunotherapy, creating a synergistic effect.

Personalized Medicine Approach

Nanotechnology facilitates a personalized medicine approach in cancer immunotherapy. The tailoring of nanocarriers to individual patient characteristics allows for customized treatment strategies. This personalized approach enhances treatment precision, potentially improving patient responses and minimizing adverse effects.

Imaging and Theranostics

Nanoparticles assume dual roles as imaging agents and therapeutic carriers, embodying a theranostic approach. This permits real-time monitoring of treatment response and disease progression. The integration of imaging capabilities into nanotherapeutics enhances the precision of cancer immunotherapy by providing insights into the distribution and efficacy of the delivered agents. The synergies between nanotechnology and cancer immunotherapy represent a frontier in the pursuit of more effective and targeted cancer treatments. As ongoing research continues to unveil the full potential of this collaboration, the integration of nanotechnology holds promise for transforming the landscape of cancer therapeutics, offering innovative solutions to overcome current challenges and enhance patient outcomes.

Challenges

Biocompatibility and Toxicity

Ensuring the biocompatibility of nanoparticles and understanding their potential toxicity pose critical challenges. A thorough evaluation of the long-term effects of nanomaterial exposure on normal tissues is imperative to address safety concerns.

Clinical Translation

Bridging the gap between preclinical success and clinical applications remains a challenge in cancer nanotechnology. The transition from laboratory studies to practical, clinically viable solutions requires rigorous testing and validation.

Clearance and Bio-distribution

Understanding the clearance and biodistribution of nanoparticles within the body is crucial. Addressing concerns related to the potential accumulation of nanoparticles in organs and tissues is essential for long-term safety.

Standardization and Regulation

Standardizing the synthesis, characterization and testing of nanoparticles is challenging but necessary to ensure consistency and reliability. Regulatory frameworks must evolve to address the unique aspects of nanomedicine and ensure patient safety.

Cost and Accessibility

The development and production of nanomedicines can be expensive. Cost considerations and accessibility issues may limit widespread adoption, particularly in resource-limited settings.

Resistance and Adaptation

Similar to traditional cancer therapies, there is a risk of cancer cells developing resistance to nano-medicines over time. Understanding and addressing mechanisms of resistance are crucial for sustained effectiveness.

Ethical Considerations

The ethical implications of nanotechnology, including potential unknown long-term effects and unintended consequences require careful consideration. Ensuring transparency & ethical use of nano-technological advancements is essential [28-33].

Conclusion

Cancer nanotechnology necessitates the collaboration among diverse scientific disciplines. Integrating knowledge from materials science, biology, medicine, and engineering poses a challenge that requires effective interdisciplinary communication. Addressing these challenges while capitalizing on the prospective advantages of cancer nanotechnology is essential for realizing its full potential in revolutionizing cancer diagnosis and treatment. Ongoing research and collaborative efforts are critical to overcoming these hurdles and advancing the integration of immunotherapy and nanotechnology for precision cancer therapy.

References

1. Friess H et al. LHRH receptors in the human pancreas. Basis for anti-hormonal treatment in ductal carcinoma of the pancreas. Int. J. Pancreatol., 1991;(10) : 151-9.
2. Abdillahi HS et al. South African plants and male reproductive healthcare: conception and contraception. J. Ethnopharmacol, 2012; 143: 475-80.
3. Marwa Hamdi et al. Design of blue crab chitosan responsive nanoparticles as controlled-release nanocarrier: Physicochemical features, thermal stability and in vitro pH-dependent delivery properties. International Journal of Biological Macromolecules, 2020; 145: 1140-54.
4. Mengdi Song et al. A nano-targeted co-delivery system based on gene regulation and molecular blocking strategy for synergistic enhancement of platinum chemotherapy sensitivity in ovarian cancer. International Journal of Pharmaceutics, 2023; 640:123022.
5. Hawkey NM, Sartor AO, Morris MJ, Armstrong AJ. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. Clin Adv Hematol Oncol. 2022 Apr;20(4):227-38.
6. Erika AK, Fletcher et al. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism of action of immune-therapeutics. International Immuno-pharmacology, 2018; 54: 1-11.
7. Sedigheh Jalali et al. Examining the impact of immunosuppressive drugs on antibody-dependent cellular cytotoxicity of human peripheral blood natural killer cells and gamma delta (γδ) T cells. Transplant Immunology, 2024; 82: 101962.

8. Katarzyna Ratajczak et al. Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosensors and Bioelectronics, 2023; 240: 115644.

9. Michael Babich et al. A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen. Heliyon, 2022; 8(3): e08988.

10. Haoyu Chen et al. Triple-Hop nano-bomb combining CDT, PDT and immunetherapy for NIR-triggered cancer therapy. Chemical Engineering Journal, 2024;481:148268.

11. Mehdi Chaib et al. Sipe PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer. Cancer Letters, April 2022; 531: 98-108.

12. Md Kamrul Hasan et al. Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells. Blood, 2023;142, (1): 26836.

13. Chu AK et al. The Supportive Care Needs of Advanced Lung Cancer Patients Receiving Immuno- and Targeted Therapy at Different Stages of the Disease Trajectory. Journal of Thoracic Oncology, 2023; 18(11): S742.

14. Nayak RK, Gerber D, Zhang C, Cohen JB. SOHO State of the Art Updates and Next Questions Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors. Clin Lymphoma Myeloma Leuk. 2023 Dec; 23(12):861-5.

15. Mohammad Saleh Sadeghi et al. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environmental Research,2023; 237(2): 117027.

16. Michelle Harriz Braga et al. Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome. Annals of Hepatology, 2023; 28(4): 101105.

17. Devesh U Kapoor et al. Garg Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results in Chemistry, 2023; 6:101167.

18. Lima EABF, Wyde RAF, Sorace AG, Yankeelov TE. Optimizing combination therapy in a murine model of HER2+ breast cancer. Comput Methods Appl Mech Eng. 2022 Dec 1; 402:115484.

19. Auletta JJ, Sandmaier BM, Jensen E, Majhail NS, Knutson J, Nemecek E, Ajayi-Hackworth F, Davies SM; ACCESS Workshop Team. The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem. Transplant Cell Ther. 2022 Dec; 28(12):802-9.

20. Piranfar A, Soltani M, Kashkooli FM, Uribe CF, Rahmim A. Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to ^{177}Lu-PSMA therapy of prostate cancer. Comput Methods Programs Biomed. 2024; 245: 108004.

21. Akshansh Sharma et al. Recent advancements in photodynamic therapy and cancer biosensor using natural products. Talanta Open, 2023; 8:100261.

22. Wenpan Li et al. Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy. International Journal of Pharmaceutics, 2023; 634: 122655.

23. Zhangyi Luo et al. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Letters, 2023; 575: 216396.

24. Xiaogang Qu et al. Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. Bioactive Materials, 2023; 24:136-52.

25. Bo Chen et al. Nano-co-delivery of an NIR photothermal agent and an acid-responsive TLR7 agonist prodrug to enhance cancer photothermal immunotherapy and the abscopal effect. Biomaterials, 2024; 305: 122434.

26. Junnan Li et al. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. Drug Resistance Updates, 2023; 66:100904.

27. Kefeng Liu et al. A novel multifunctional vaccine platform with dendritic cell-targeting and pH-responsive for cancer immunotherapy: Antigen-directed biomimetic fabrication of a cabbage-like mannatide-zinc-antigen hybrid microparticles. Chemical Engineering, 2021; 426: 130867.

28. Virender Kumar et al. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. Cancer Letters, 2023; 579: 216462.

29. Lu Shi et al. Cell membrane-camouflaged liposomes and neopeptide-loaded liposomes with TLR agonist R848 provides a prime and boost strategy for efficient personalized cancer vaccine therapy Nanomedicine: Nanotechnology, Biology and Medicine. 2023; 48: 102648.

30. Preeti Sakore et al. The theranostic potential of green nanotechnology-enabled gold nanoparticles in cancer: A paradigm shift on diagnosis and treatment approaches. Results in Chemistry, 2024; 7: 101264.

31. Weiguo Chen et al. Hypoxia-responsive immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy for potentiating cancer immunotherapy. Chemical Engineering Journal, 2023; 451: 2138781.

32. Fanqi Liu et al. A versatile nano-transformer for efficient localization-specific imaging and synergistic therapy of bladder cancer. Nano Today, 2024; 54: 102116.

33. Bartkowski M, Bincoletto V, Salaroglio IC, Ceccone G, Arenal R, Nervo S, Rolando B, Riganti C, Arpicco S, Giordani S. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs. J Colloid Interface Sci. 2024; 659: 339-54.